Cell Medx Corp. (CMXC) 0.1600 $CMXC
Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
Marketwired - Mon Apr 13, 7:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company"
is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
Penny Stocks Research for WINDSTREAM, Fastfunds Financial, ScripsAmerica, OSL Holdings, AVRA, and Cell MedX
PR Newswire - Fri Apr 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: WINDSTREAM (OTCMKTS:WSTI), Fastfunds Financial (OTCMKTS:FFFC), ScripsAmerica (OTCMKTS:SCRC), OSL Holdings (OTCMKTS:OSLH), AVRA (OTCBB:AVRN), and Cell MedX (OTCBB:CMXC).
Cell MedX begins trading on OTCQB venture stage marketplace from 18 February
M2 - Thu Feb 19, 6:31AM CST
Cell MedX Corp (OTC PINK: CMXC) (OTCQB: CMXC) announced on Wednesday the receipt of an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace.
Cell MedX Corp. (CMXC) Commences Trading on OTCQB Venture Stage Marketplace
Marketwired - Wed Feb 18, 7:50AM CST
Cell MedX Corp. (OTC PINK: CMXC) (OTCQB: CMXC), (the "Company" is pleased to announce that the Company has received an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace. The Company will transition from the OTC Pink open marketplace to the OTCQB on February 18, 2015.
Cell MedX Corp. (CMXC) Disavows Coverage by The Moskowitz Report and The SmallCap Network
Marketwired - Tue Jan 27, 2:58PM CST
Cell MedX Corp. (OTC PINK: CMXC), (the "Company" has become aware of a paid report on the Company prepared and published by The Moskowitz Report dated Winter 2015, and additional reports on the Company prepared by James E. Brumley as a contributor for, and published by, the Small Cap Network dated January 13, 2015, January 21, 2015, and January 26, 2015. The Company believes that the above referenced reports do not provide an accurate portrayal of the Company, its business or its future prospects. Furthermore, the Company has not approved, authorized or participated in the creation of the reports prepared and published by The Moskowitz Report, the Small Cap Network, or any other third parties. The Company advises investors not to rely on these reports for information regarding the Company.
Cell MedX engages The Metabolomics Innovation Centre to explore metabolic foundations of diabetes management platform
M2 - Tue Jan 27, 3:37AM CST
Cell MedX Corp (OTC: CMXC), an early development stage company focused on the discovery, development and commercialisation of therapeutic products to help manage the illness and related complications of diseases like diabetes, announced on Monday that it has engaged the Metabolomics Innovation Centre at the University of Alberta (TMIC) to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which it commenced on 9 January 2015.
Cell MedX Corp.: Multiple Name Changes, Insider Ownership, And Poor Financials
Hunter Straus - at Seeking Alpha - Mon Jan 26, 11:57AM CST
Cell MedX Corp. (CMXC) Announces Engagement of The Metabolomics Innovation Centre
Marketwired - Mon Jan 26, 7:01AM CST
Cell MedX Corp. (OTC: CMXC), (the "Company" announced today that the Company has engaged The Metabolomics Innovation Centre at the University of Alberta ("TMIC" to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which the Company commenced on January 9, 2015.
Cell MedX to commence pilot trial of e-balance technology on 9 January 2015
M2 - Tue Jan 06, 5:20AM CST
Cell MedX Corp (OTCBB: CMXC) announced on Monday that it has scheduled the commencement of its pilot trial of the e-balance technology for 9 January 2015.
Cell MedX Corp. (CMXC) Announces Commencement of the Pilot Trial of Its e-balance Technology
Marketwired - Mon Jan 05, 7:02AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company" announced today that the Company has scheduled the commencement of its pilot trial of the e-balance Technology for January 9, 2015.
Cell MedX Corp. (CMXC) Announces Change of Auditors
Marketwired - Wed Dec 24, 8:00AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company" announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC. The decision to change auditors was not the result of any disagreement between the Company and Sadler, Gibb & Associates, LLC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
Cell MedX Corp's new subsidiary receives USD55,000 first order
M2 - Fri Dec 19, 3:30AM CST
Cell MedX Corp (OTCBB: CMXC) announced on Thursday that its newly formed wholly owned subsidiary, Avyonce Cosmedics Inc, has received its first order for approximately USD55,000 from Dubai, UAE.
Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary
Marketwired - Thu Dec 18, 7:02AM CST
Cell MedX Corp. (OTCBB: CMXC) (the "Company" is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. ("Avyonce". Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry. Avyonce has received its first order for approximately US$55,000 from Dubai, United Arab Emirates.
Cell MedX completes acquisition of proprietary technology for treating diabetes and related ailments
M2 - Thu Nov 27, 4:14AM CST
Cell MedX Corp (OTCBB:CMXC), an early development stage company focused on the development and commercialisation of therapeutic solutions, announced on Wednesday the completion of the acquisition of a proprietary technology for the treatment of diabetes and related ailments from the inventors of this technology, Jean Arnett and Bradley Hargreaves.
Cell MedX Corp. (CMXC), Announces Acquisition of Proprietary Technology for Treatment of Diabetes and Related Ailments
Marketwired - Wed Nov 26, 8:00AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company" announced today that it has completed the acquisition of a proprietary technology for the treatment of diabetes and related ailments (the "Technology" from the inventors of the Technology, Jean Arnett and Bradley Hargreaves.
Cell MedX Corp. (CMXC), Announces the formation of an Advisory Board with John Sanderson MD as Chairman
Marketwired - Tue Nov 11, 7:04AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company" announces the formation of an Advisory Board with Dr. John Sanderson MD as its Chairman. Dr. Sanderson will be organizing the development team and protocols necessary to advance the development of the Company's proposed technology, including the clinical trial phases and oversight of the results of those trials. Dr. Sanderson is accepting this appointment as an interim position in the anticipation of joining the Company as its Chief Medical Director. Dr. Sanderson is a stem cell researcher who began his career in clinical medicine specializing in diabetes and intravenous nutrition of critically ill patients. He has received NIH funding, has multiple issued patents and published numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers and acquisitions, formulating strategic initiatives, and evaluating new technologies. As a consultant to Fortune 100 health care companies and the U.S. government, Dr. Sanderson worked with some of the greatest minds of the day devising technological solutions to important public health challenges such as obesity, diabetes, and asthma.
Cell MedX Corp. Announces Signing of Definitive Agreement to Acquire Technology for Treating Diabetes and Related Ailments
Marketwired - Fri Oct 17, 8:02AM CDT
Cell MedX Corp. (OTCBB: CMXC), (the "Company" is pleased to announce that on October 16, 2014, the Company entered into a Technology Purchase Agreement with Jean Arnett and Brad Hargreaves (collectively being the "Vendors" to acquire a proprietary technology for treatment of diabetes and related ailments (the "Technology". The Purchase Agreement replaces and supersedes the binding letter agreement dated August 29, 2014, pursuant to which the Vendors had previously agreed to grant to the Company exclusive worldwide license rights for the Technology.
Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
Marketwired - Mon Apr 13, 7:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company"
is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. Penny Stocks Research for WINDSTREAM, Fastfunds Financial, ScripsAmerica, OSL Holdings, AVRA, and Cell MedX
PR Newswire - Fri Apr 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: WINDSTREAM (OTCMKTS:WSTI), Fastfunds Financial (OTCMKTS:FFFC), ScripsAmerica (OTCMKTS:SCRC), OSL Holdings (OTCMKTS:OSLH), AVRA (OTCBB:AVRN), and Cell MedX (OTCBB:CMXC).
Cell MedX begins trading on OTCQB venture stage marketplace from 18 February
M2 - Thu Feb 19, 6:31AM CST
Cell MedX Corp (OTC PINK: CMXC) (OTCQB: CMXC) announced on Wednesday the receipt of an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace.
Cell MedX Corp. (CMXC) Commences Trading on OTCQB Venture Stage Marketplace
Marketwired - Wed Feb 18, 7:50AM CST
Cell MedX Corp. (OTC PINK: CMXC) (OTCQB: CMXC), (the "Company"
is pleased to announce that the Company has received an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace. The Company will transition from the OTC Pink open marketplace to the OTCQB on February 18, 2015. Cell MedX Corp. (CMXC) Disavows Coverage by The Moskowitz Report and The SmallCap Network
Marketwired - Tue Jan 27, 2:58PM CST
Cell MedX Corp. (OTC PINK: CMXC), (the "Company"
has become aware of a paid report on the Company prepared and published by The Moskowitz Report dated Winter 2015, and additional reports on the Company prepared by James E. Brumley as a contributor for, and published by, the Small Cap Network dated January 13, 2015, January 21, 2015, and January 26, 2015. The Company believes that the above referenced reports do not provide an accurate portrayal of the Company, its business or its future prospects. Furthermore, the Company has not approved, authorized or participated in the creation of the reports prepared and published by The Moskowitz Report, the Small Cap Network, or any other third parties. The Company advises investors not to rely on these reports for information regarding the Company. Cell MedX engages The Metabolomics Innovation Centre to explore metabolic foundations of diabetes management platform
M2 - Tue Jan 27, 3:37AM CST
Cell MedX Corp (OTC: CMXC), an early development stage company focused on the discovery, development and commercialisation of therapeutic products to help manage the illness and related complications of diseases like diabetes, announced on Monday that it has engaged the Metabolomics Innovation Centre at the University of Alberta (TMIC) to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which it commenced on 9 January 2015.
Cell MedX Corp.: Multiple Name Changes, Insider Ownership, And Poor Financials
Hunter Straus - at Seeking Alpha - Mon Jan 26, 11:57AM CST
Cell MedX Corp. (CMXC) Announces Engagement of The Metabolomics Innovation Centre
Marketwired - Mon Jan 26, 7:01AM CST
Cell MedX Corp. (OTC: CMXC), (the "Company"
announced today that the Company has engaged The Metabolomics Innovation Centre at the University of Alberta ("TMIC" to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which the Company commenced on January 9, 2015. Cell MedX to commence pilot trial of e-balance technology on 9 January 2015
M2 - Tue Jan 06, 5:20AM CST
Cell MedX Corp (OTCBB: CMXC) announced on Monday that it has scheduled the commencement of its pilot trial of the e-balance technology for 9 January 2015.
Cell MedX Corp. (CMXC) Announces Commencement of the Pilot Trial of Its e-balance Technology
Marketwired - Mon Jan 05, 7:02AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company"
announced today that the Company has scheduled the commencement of its pilot trial of the e-balance Technology for January 9, 2015. Cell MedX Corp. (CMXC) Announces Change of Auditors
Marketwired - Wed Dec 24, 8:00AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company"
announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC. The decision to change auditors was not the result of any disagreement between the Company and Sadler, Gibb & Associates, LLC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. Cell MedX Corp's new subsidiary receives USD55,000 first order
M2 - Fri Dec 19, 3:30AM CST
Cell MedX Corp (OTCBB: CMXC) announced on Thursday that its newly formed wholly owned subsidiary, Avyonce Cosmedics Inc, has received its first order for approximately USD55,000 from Dubai, UAE.
Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary
Marketwired - Thu Dec 18, 7:02AM CST
Cell MedX Corp. (OTCBB: CMXC) (the "Company"
is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. ("Avyonce". Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry. Avyonce has received its first order for approximately US$55,000 from Dubai, United Arab Emirates. Cell MedX completes acquisition of proprietary technology for treating diabetes and related ailments
M2 - Thu Nov 27, 4:14AM CST
Cell MedX Corp (OTCBB:CMXC), an early development stage company focused on the development and commercialisation of therapeutic solutions, announced on Wednesday the completion of the acquisition of a proprietary technology for the treatment of diabetes and related ailments from the inventors of this technology, Jean Arnett and Bradley Hargreaves.
Cell MedX Corp. (CMXC), Announces Acquisition of Proprietary Technology for Treatment of Diabetes and Related Ailments
Marketwired - Wed Nov 26, 8:00AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company"
announced today that it has completed the acquisition of a proprietary technology for the treatment of diabetes and related ailments (the "Technology" from the inventors of the Technology, Jean Arnett and Bradley Hargreaves. Cell MedX Corp. (CMXC), Announces the formation of an Advisory Board with John Sanderson MD as Chairman
Marketwired - Tue Nov 11, 7:04AM CST
Cell MedX Corp. (OTCBB: CMXC), (the "Company"
announces the formation of an Advisory Board with Dr. John Sanderson MD as its Chairman. Dr. Sanderson will be organizing the development team and protocols necessary to advance the development of the Company's proposed technology, including the clinical trial phases and oversight of the results of those trials. Dr. Sanderson is accepting this appointment as an interim position in the anticipation of joining the Company as its Chief Medical Director. Dr. Sanderson is a stem cell researcher who began his career in clinical medicine specializing in diabetes and intravenous nutrition of critically ill patients. He has received NIH funding, has multiple issued patents and published numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers and acquisitions, formulating strategic initiatives, and evaluating new technologies. As a consultant to Fortune 100 health care companies and the U.S. government, Dr. Sanderson worked with some of the greatest minds of the day devising technological solutions to important public health challenges such as obesity, diabetes, and asthma. Cell MedX Corp. Announces Signing of Definitive Agreement to Acquire Technology for Treating Diabetes and Related Ailments
Marketwired - Fri Oct 17, 8:02AM CDT
Cell MedX Corp. (OTCBB: CMXC), (the "Company"
is pleased to announce that on October 16, 2014, the Company entered into a Technology Purchase Agreement with Jean Arnett and Brad Hargreaves (collectively being the "Vendors" to acquire a proprietary technology for treatment of diabetes and related ailments (the "Technology". The Purchase Agreement replaces and supersedes the binding letter agreement dated August 29, 2014, pursuant to which the Vendors had previously agreed to grant to the Company exclusive worldwide license rights for the Technology. 
